Valuation: MiNK Therapeutics, Inc.

Market Cap 56.15M 48.49M 45.57M 41.44M 77.91M 5.37B 79.2M 534M 209M 2.69B 211M 206M 8.93B P/E 2026 *
-5.84x
P/E 2027 * -4.26x
Enterprise Value 56.15M 48.49M 45.57M 41.44M 77.91M 5.37B 79.2M 534M 209M 2.69B 211M 206M 8.93B EV / Sales 2026 *
16.5x
EV / Sales 2027 * 28.1x
Free-Float
38.4%
Yield 2026 *
-
Yield 2027 * -
1 day+2.45%
1 week+2.92%
Current month+7.33%
1 month+1.62%
3 months+5.13%
6 months+2.08%
Current year+1.08%
1 week 10.8
Extreme 10.8
11.6
1 month 10.21
Extreme 10.21
11.97
Current year 8.48
Extreme 8.4801
16.93
1 year 8.48
Extreme 8.4801
16.98
3 years 4.56
Extreme 4.5601
76
5 years 4.56
Extreme 4.5601
221.55
10 years 4.56
Extreme 4.5601
221.55
Manager TitleAgeSince
Chief Executive Officer 52 2021-01-31
Director of Finance/CFO 37 2026-03-12
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 52 2021-01-31
Chairman 73 2017-06-30
Director/Board Member 62 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
2/27/26 Sell

Director

500 0.0107%
1/2/26 Free

Director

5,395 0.1149%
1/2/26 Free

Director

5,395 0.1149%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%+2.92%-24.41%-34.09% 56.15M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.35%+0.73%+66.64%+94.40% 26.32B
Weighted average by Cap. -0.91%+0.59%+95.80%+132.91%

Financials

2026 *2027 *
Net sales 3.4M 2.94M 2.76M 2.51M 4.72M 325M 4.8M 32.33M 12.64M 163M 12.77M 12.49M 541M 2M 1.73M 1.62M 1.48M 2.78M 191M 2.82M 19.02M 7.44M 95.77M 7.51M 7.35M 318M
Net income -9.6M -8.29M -7.79M -7.09M -13.32M -918M -13.54M -91.29M -35.69M -460M -36.04M -35.26M -1.53B -15.1M -13.04M -12.25M -11.14M -20.95M -1.44B -21.3M -144M -56.13M -723M -56.68M -55.45M -2.4B
Net Debt - -
Logo MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Employees
15
Date Price Change Volume
26-08-14 US$11.27 +2.45% 6,787
26-08-13 US$11.00 -3.17% 8,605
26-08-12 US$11.36 +1.16% 4,718
26-08-11 US$11.23 +2.56% 5,917
26-08-10 US$10.95 0.00% 5,136
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.27USD
Average target price
39.00USD
Spread / Average Target
+246.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INKT Stock